Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance

Collagen prolyl 4-hydroxylase (P4H) expression and collagen hydroxylation in cancer cells are necessary for breast cancer progression. Here, we show that P4H alpha 1 subunit (P4HA1) protein expression is induced in triple-negative breast cancer (TNBC) and HER2 positive breast cancer. By modulating alpha ketoglutarate (α-KG) and succinate levels P4HA1 expression reduces proline hydroxylation on hypoxia-inducible factor (HIF) 1α, enhancing its stability in cancer cells. Activation of the P4HA/HIF-1 axis enhances cancer cell stemness, accompanied by decreased oxidative phosphorylation and reactive oxygen species (ROS) levels. Inhibition of P4HA1 sensitizes TNBC to the chemotherapeutic agent docetaxel and doxorubicin in xenografts and patient-derived models. We also show that increased P4HA1 expression correlates with short relapse-free survival in TNBC patients who received chemotherapy. These results suggest that P4HA1 promotes chemoresistance by modulating HIF-1-dependent cancer cell stemness. Targeting collagen P4H is a promising strategy to inhibit tumor progression and sensitize TNBC to chemotherapeutic agents.Hyperactivation of HIF-1α is crucial in progression of triple-negative breast cancer, but how HIF-1α stability is maintained in a hypoxia-independent manner is unclear. Here, the authors show collagen prolyl-4-hydroylase 1 stabilises HIF-1α and is involved in chemoresistance in TNBC.

[1]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[2]  J. Ramshaw,et al.  Gly-X-Y tripeptide frequencies in collagen: a context for host-guest triple-helical peptides. , 1998, Journal of structural biology.

[3]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Cheng Cheng Zhang,et al.  The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. , 2010, Cell stem cell.

[5]  Hua Yu,et al.  Erratum: JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance (Cell Metabolism (2018) 27(1) (136–150.e5)(S1550413117306691)(10.1016/j.cmet.2017.11.001)) , 2018 .

[6]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[7]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[8]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[9]  S. Bicciato,et al.  SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors , 2012, Nature.

[10]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Andrew N Lane,et al.  Isotopomer-based metabolomic analysis by NMR and mass spectrometry. , 2008, Methods in cell biology.

[12]  P. Ratcliffe,et al.  HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O2 levels , 2003, Journal of Cell Science.

[13]  Andrew N Lane,et al.  Applications of NMR spectroscopy to systems biochemistry. , 2016, Progress in nuclear magnetic resonance spectroscopy.

[14]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[15]  M. Ferrari,et al.  XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.

[16]  K. Kivirikko,et al.  The Novel Type II Prolyl 4-Hydroxylase Is the Main Enzyme Form in Chondrocytes and Capillary Endothelial Cells, whereas the Type I Enzyme Predominates in Most Cells* , 1998, The Journal of Biological Chemistry.

[17]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[18]  S. Ghaffari,et al.  Stem cells and the impact of ROS signaling , 2014, Development.

[19]  J. Caro,et al.  Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. , 1999, Biochemical and biophysical research communications.

[20]  E. Gottlieb,et al.  Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells , 2007, Molecular and Cellular Biology.

[21]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[22]  Keisuke Ito,et al.  Metabolic requirements for the maintenance of self-renewing stem cells , 2014, Nature Reviews Molecular Cell Biology.

[23]  G. Semenza.  Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. , 2012, Trends in molecular medicine.

[24]  Brian Keith,et al.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.

[25]  P. Real,et al.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells , 2002, Oncogene.

[26]  I. Ellis,et al.  Triple‐negative/basal‐like breast cancer: review , 2009, Pathology.

[27]  G. Semenza,et al.  Collagen prolyl hydroxylases are essential for breast cancer metastasis. , 2013, Cancer research.

[28]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[29]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[30]  Jieqing Zhu,et al.  Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition , 2014, BMC Cancer.

[31]  G. Semenza,et al.  Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[32]  Michael Q. Zhang,et al.  An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia , 2009, Nucleic acids research.

[33]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[34]  Edward Kai-Hua Chow,et al.  Mechanisms of chemoresistance in cancer stem cells , 2013, Clinical and Translational Medicine.

[35]  Tim Rappon,et al.  Overexpression of Pyruvate Dehydrogenase Kinase 1 and Lactate Dehydrogenase A in Nerve Cells Confers Resistance to Amyloid β and Other Toxins by Decreasing Mitochondrial Respiration and Reactive Oxygen Species Production* , 2012, The Journal of Biological Chemistry.

[36]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[37]  Manuela Milani,et al.  Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[39]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[40]  C. Rueden,et al.  Bmc Medicine Collagen Density Promotes Mammary Tumor Initiation and Progression , 2022 .

[41]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[42]  Sendurai A Mani,et al.  The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies , 2009, Journal of Mammary Gland Biology and Neoplasia.

[43]  J. Ingels,et al.  Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer , 2012, Breast Cancer Research.

[44]  Hua Yu,et al.  JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. , 2018, Cell metabolism.

[45]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[46]  Hua Yu,et al.  JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. , 2018, Cell metabolism.

[47]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[48]  S. Sharkis,et al.  A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. , 2007, Blood.

[49]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[50]  J. Caro,et al.  Hypoxia-inducible Factor 1α (HIF-1α) Protein Is Rapidly Degraded by the Ubiquitin-Proteasome System under Normoxic Conditions , 1997, The Journal of Biological Chemistry.

[51]  Denis Wirtz,et al.  Hypoxia-inducible Factor 1 (HIF-1) Promotes Extracellular Matrix Remodeling under Hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 Expression in Fibroblasts* , 2013, The Journal of Biological Chemistry.

[52]  Manuela Milani,et al.  Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.

[53]  R. DePinho,et al.  Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. El-Deiry,et al.  HIF-1 signaling in drug resistance to chemotherapy. , 2014, Current medicinal chemistry.

[55]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[56]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[57]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[58]  J. Hassell,et al.  A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer , 2012, Scientific Reports.

[59]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[60]  Gordon Keller,et al.  Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids , 2015, Nature Medicine.

[61]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.

[62]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[63]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[64]  Ronald T. Raines,et al.  Prolyl 4-hydroxylase , 2010, Critical reviews in biochemistry and molecular biology.

[65]  V. Cryns,et al.  Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.

[66]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[67]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  P. Ratcliffe,et al.  Independent function of two destruction domains in hypoxia‐inducible factor‐α chains activated by prolyl hydroxylation , 2001, The EMBO journal.

[69]  K. Kivirikko,et al.  Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor* , 2003, Journal of Biological Chemistry.

[70]  G. Semenza,et al.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.

[71]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.